SMT201400024B - Inibitore del bromodominio di benzodiazepine - Google Patents

Inibitore del bromodominio di benzodiazepine

Info

Publication number: SMT201400024B
Authority: SM; San Marino
Prior art keywords: benzodiazepines; bromodomain inhibitor; bromodomain; inhibitor
Prior art date: 2009-11-05

Application number

SM201400024T

Other languages

English (en)

Italian (it)

Inventor

Romain Luc Marie Gosmini

Olivier Mirguet

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-05

Filing date

2014-02-20

Publication date

2014-07-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42667965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-05 Priority claimed from GB0919433A external-priority patent/GB0919433D0/en

2010-06-22 Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en

2014-02-20 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2014-07-07 Publication of SMT201400024B publication Critical patent/SMT201400024B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SM201400024T 2009-11-05 2014-02-20 Inibitore del bromodominio di benzodiazepine SMT201400024B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0919433A GB0919433D0 (en)	2009-11-05	2009-11-05	Novel compounds
GBGB1010509.6A GB201010509D0 (en)	2010-06-22	2010-06-22	Novel compounds
PCT/EP2010/061518 WO2011054553A1 (en)	2009-11-05	2010-08-06	Benzodiazepine bromodomain inhibitor

Publications (1)

Publication Number	Publication Date
SMT201400024B true SMT201400024B (it)	2014-07-07

Family

ID=42667965

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SM201400024T SMT201400024B (it)	2009-11-05	2014-02-20	Inibitore del bromodominio di benzodiazepine
SM201600081T SMT201600081B (it)	2009-11-05	2016-03-22	Inibitore di bromodominio di benzodiazepina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SM201600081T SMT201600081B (it)	2009-11-05	2016-03-22	Inibitore di bromodominio di benzodiazepina

Country Status (33)

Country	Link
US (3)	US9023842B2 (es)
EP (3)	EP2722334B1 (es)
JP (1)	JP5524343B2 (es)
KR (1)	KR101424989B1 (es)
CN (1)	CN102762569B (es)
AU (1)	AU2010314395B2 (es)
BR (1)	BR112012010706A2 (es)
CA (1)	CA2779355C (es)
CL (1)	CL2012001178A1 (es)
CO (1)	CO6540003A2 (es)
CR (1)	CR20120283A (es)
CY (2)	CY1114988T1 (es)
DK (2)	DK2496580T3 (es)
DO (1)	DOP2012000114A (es)
EA (1)	EA020390B1 (es)
ES (3)	ES2652304T3 (es)
HK (1)	HK1220188A1 (es)
HR (2)	HRP20140107T1 (es)
HU (1)	HUE026421T2 (es)
IL (2)	IL219090A0 (es)
MA (1)	MA33803B1 (es)
ME (1)	ME02360B (es)
MX (1)	MX2012005295A (es)
MY (1)	MY160456A (es)
NZ (1)	NZ599258A (es)
PE (1)	PE20121181A1 (es)
PH (1)	PH12012500894A1 (es)
PL (2)	PL2722334T3 (es)
PT (2)	PT2722334E (es)
RS (2)	RS54592B1 (es)
SI (2)	SI2722334T1 (es)
SM (2)	SMT201400024B (es)
WO (1)	WO2011054553A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2564318T3 (es) *	2009-11-05	2016-03-21	Glaxosmithkline Llc	Inhibidor de bromodominio de benzodiazepina
GB0919432D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
CA2799403C (en)	2010-05-14	2020-01-21	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating leukemia
CA2799420C (en)	2010-05-14	2018-10-02	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating neoplasia, inflammatory disease and other disorders
US9301962B2 (en)	2010-05-14	2016-04-05	Baylor College Of Medicine	Male contraceptive compositions and methods of use
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en)	2010-12-02	2016-02-02	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
US9422292B2 (en)	2011-05-04	2016-08-23	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
US9328117B2 (en)	2011-06-17	2016-05-03	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2013027168A1 (en)	2011-08-22	2013-02-28	Pfizer Inc.	Novel heterocyclic compounds as bromodomain inhibitors
DE102011082013A1 (de)	2011-09-01	2013-03-07	Bayer Pharma AG	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en)	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
CN104334526A (zh)	2012-04-20	2015-02-04	艾伯维公司	异吲哚酮衍生物
WO2013184878A1 (en)	2012-06-06	2013-12-12	Constellation Pharmaceuticals, Inc.	Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
TWI602820B (zh)	2012-06-06	2017-10-21	星宿藥物公司	溴域抑制劑及其用途
BR112014031068A2 (pt)	2012-06-12	2017-06-27	Abbvie Inc	derivados piridinona e piridazinona
ES2628005T3 (es)	2012-08-16	2017-08-01	Bayer Pharma Aktiengesellschaft	2,3-Benzodiazepinas
EP2884983B1 (en) *	2012-08-16	2017-10-04	GlaxoSmithKline LLC	Benzodiazepines for treating small cell lung cancer
JP6276277B2 (ja)	2012-09-28	2018-02-07	バイエルファーマアクチエンゲゼルシャフト	Ｂｅｔタンパク質阻害性の５−アリールトリアゾロアゼピン
US9422290B2 (en)	2012-11-13	2016-08-23	Boehringer Ingelheim International Gmbh	Triazolopyridazine
US9266891B2 (en)	2012-11-16	2016-02-23	Boehringer Ingelheim International Gmbh	Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en)	2012-12-21	2018-08-01	Zenith Epigenetics Ltd.	Novel heterocyclic compounds as bromodomain inhibitors
US9492460B2 (en) *	2013-02-27	2016-11-15	Bristol-Myers Squibb Company	Carbazole compounds useful as bromodomain inhibitors
EP2961411A4 (en) *	2013-02-28	2016-11-23	Univ Washington	METHOD FOR TREATING INFECTIONS WITH HUMAN CYTOMAL GALOVIRUS AND DISEASES WITH BROMDOMAIN DISEASES
JP2016512524A (ja) *	2013-03-11	2016-04-28	アッヴィ・インコーポレイテッド	ブロモドメイン阻害剤
EP2970285B1 (en)	2013-03-11	2019-04-17	AbbVie Inc.	Fused tetracyclic bromodomain inhibitors
WO2014159837A1 (en) *	2013-03-14	2014-10-02	Convergene Llc	Methods and compositions for inhibition of bromodomain-containing proteins
US9714946B2 (en)	2013-03-14	2017-07-25	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
AU2014230816B9 (en) *	2013-03-14	2016-12-15	Glaxosmithkline Intellectual Property (No.2) Limited	Furopyridines as bromodomain inhibitors
EP3581576B1 (en)	2013-03-15	2022-01-26	Incyte Holdings Corporation	Tricyclic heterocycles as bet protein inhibitors for use in the treatment of a proliferative disease in combination with a janus kinase inhibitor
EP2792355A1 (en)	2013-04-17	2014-10-22	Albert-Ludwigs-Universität Freiburg	Compounds for use as bromodomain inhibitors
EP2989096B1 (en)	2013-04-26	2019-04-10	BeiGene, Ltd.	Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
SI3010503T1 (sl)	2013-06-21	2020-07-31	Zenith Epigenetics Ltd.	Novi biciklični inhibitorji bromodomene
EP3010918B1 (en)	2013-06-21	2018-08-15	Zenith Epigenetics Ltd.	Novel substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) *	2013-06-28	2016-02-03	Abbvie Inc	Inhibidores cristalinos de bromodominios
WO2015006193A1 (en)	2013-07-08	2015-01-15	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
JP2016531113A (ja)	2013-07-25	2016-10-06	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	転写因子の阻害剤およびその使用
JP6542212B2 (ja)	2013-07-31	2019-07-10	ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＬｔｄ．	ブロモドメイン阻害剤としての新規キナゾリノン
US9428513B2 (en)	2013-11-07	2016-08-30	Boehringer Ingelheim International Gmbh	Triazolopyrazine
MX379463B (es)	2013-11-08	2025-03-10	Dana Farber Cancer Inst Inc	Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
US9399640B2 (en)	2013-11-26	2016-07-26	Incyte Corporation	Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
GB201320994D0 (en) *	2013-11-28	2014-01-15	Univ Dundee	Enzyme function probes
WO2015095492A1 (en)	2013-12-19	2015-06-25	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
MX2016009974A (es)	2014-01-31	2016-10-31	Dana Farber Cancer Inst Inc	Derivados de diaminopirimidina bencensulfona y sus usos.
RU2016134941A (ru)	2014-01-31	2018-03-01	Дана-Фарбер Кансер Институт, Инк.	Производные диазепана и их применения
WO2015117087A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
AU2015213595A1 (en) *	2014-02-10	2016-09-08	Salk Institute For Biological Studies	Increasing storage of vitamin A, vitamin D and/or lipids
US9694017B2 (en)	2014-02-10	2017-07-04	Concert Pharmaceuticals, Inc.	Substituted triazolobenzodiazepines
WO2015121230A1 (de) *	2014-02-14	2015-08-20	Bayer Pharma Aktiengesellschaft	9-substituierte 2,3-benzodiazepine
RU2722179C2 (ru)	2014-02-28	2020-05-28	Тэнша Терапеутикс, Инк.	Лечение состояний, ассоциированных с гиперинсулинемией
US9884874B2 (en)	2014-04-09	2018-02-06	Kainos Medicine, Inc.	Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
NZ763740A (en)	2014-04-23	2023-06-30	Incyte Holdings Corp	1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
ES2725928T3 (es)	2014-06-20	2019-09-30	Constellation Pharmaceuticals Inc	Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida
NO2719005T3 (es)	2014-07-28	2018-01-20
WO2016016316A1 (en) *	2014-08-01	2016-02-04	Nuevolution A/S	Compounds active towards bromodomains
KR20170032474A (ko)	2014-08-08	2017-03-22	다나-파버 캔서 인스티튜트 인크.	디히드로프테리디논 유도체 및 그의 용도
EP3177626A4 (en)	2014-08-08	2017-12-27	Dana Farber Cancer Institute, Inc.	Diazepane derivatives and uses thereof
ES2855225T3 (es)	2014-09-15	2021-09-23	Incyte Corp	Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CA2960090A1 (en)	2014-10-02	2016-04-07	Glaxosmithkline Intellectual Property (No.2) Limited	Compound
BR112017008714A2 (pt)	2014-10-27	2017-12-19	Tensha Therapeutics Inc	inibidores de bromodomínio
CA2966298A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
HK1246273B (en)	2014-12-01	2019-12-06	恒翼生物医药(上海)股份有限公司	Substituted pyridines as bromodomain inhibitors
SG11201704089UA (en) *	2014-12-05	2017-06-29	H Lee Moffitt Cancer Ct & Res	Bromodomain inhibitor as adjuvant in cancer immunotherapy
CA2966449A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en)	2014-12-17	2018-07-18	Zenith Epigenetics Ltd.	Inhibitors of bromodomains
EP3253756B1 (en)	2015-02-03	2021-09-22	Trillium Therapeutics Inc.	Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
GB201504694D0 (en)	2015-03-19	2015-05-06	Glaxosmithkline Ip Dev Ltd	Covalent conjugates
EP4086264B1 (en)	2015-05-18	2023-10-25	Sumitomo Pharma Oncology, Inc.	Alvocidib prodrugs having increased bioavailability
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
HK1252062A1 (zh)	2015-06-26	2019-05-10	腾沙治疗公司	Nut中线癌的治疗
JP6765622B2 (ja)	2015-07-17	2020-10-07	日本光電工業株式会社	救命支援装置
KR20180049058A (ko)	2015-09-11	2018-05-10	다나-파버 캔서 인스티튜트 인크.	시아노 티에노트리아졸로디아제핀 및 그의 용도
CA2996977A1 (en)	2015-09-11	2017-03-16	Dana-Farber Cancer Institute, Inc.	Acetamide thienotriazolodiazepines and uses thereof
BR112018006689A2 (pt) *	2015-10-02	2018-10-09	Dana Farber Cancer Inst Inc	terapia de combinação de inibidores de bromodomínio e bloqueio de ponto de controle
TW201722966A (zh)	2015-10-29	2017-07-01	英塞特公司	Bet蛋白質抑制劑之非晶固體形式
SG10201913450PA (en)	2015-11-25	2020-03-30	Dana Farber Cancer Inst Inc	Bivalent bromodomain inhibitors and uses thereof
EP3442972B1 (en)	2016-04-15	2020-03-04	AbbVie Inc.	Bromodomain inhibitors
MD3472157T2 (ro)	2016-06-20	2023-10-31	Incyte Corp	Forme cristaline solide ale unui inhibitor BET
EP3490552B1 (en)	2016-07-26	2022-11-23	University of Southern California	Selective bromodomain inhibition of fungal bdf1
EP3539960A4 (en)	2016-11-10	2020-03-18	Luoxin Pharmaceutical (Shanghai) Co., Ltd.	NITROGEN MACROCYCLIC COMPOUND, ITS PREPARATION METHOD, ITS PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CN107759607B (zh) *	2017-11-29	2019-08-23	上海万巷制药有限公司	具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
AU2019391097B2 (en)	2018-12-04	2025-07-03	Sumitomo Pharma America, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2021175432A1 (en)	2020-03-04	2021-09-10	Boehringer Ingelheim International Gmbh	Method for administration of an anti cancer agent
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
US12187816B2 (en)	2020-06-23	2025-01-07	Genentech, Inc.	Macrocyclic compounds and methods of use thereof
GB202016977D0 (en)	2020-10-26	2020-12-09	In4Derm Ltd	Compounds
CN115427407B (zh)	2020-12-01	2024-02-27	成都苑东生物制药股份有限公司	一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
WO2023275542A1 (en)	2021-06-29	2023-01-05	Tay Therapeutics Limited	Pyrrolopyridone derivatives useful in the treatment of cancer
EP4511119A1 (en)	2022-04-19	2025-02-26	Nuevolution A/S	Compounds active towards bromodomains
US20260000642A1 (en)	2022-07-21	2026-01-01	Tay Therapeutics Limited	Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3610848A1 (de) *	1986-04-01	1987-10-15	Boehringer Ingelheim Kg	Neue 1,4-diazepine
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
EP0638560A4 (en)	1991-10-11	1995-03-29	Yoshitomi Pharmaceutical	MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
JPH06128257A (ja)	1992-10-13	1994-05-10	Yoshitomi Pharmaceut Ind Ltd	ピリドジアゼピン化合物
EP0730596A4 (en)	1993-11-22	1997-07-30	Merck & Co Inc	BENZODIAZEPINE
IT1285567B1 (it)	1996-02-21	1998-06-18	Alfa Chem Ital	Nuovo processo per la sintesi del nabumetone
AU3106197A (en)	1996-06-12	1998-01-07	Japan Tobacco Inc.	Cytokine production inhibitors, triazepine compounds, and intermediates there of
EA001732B1 (ru)	1996-09-13	2001-08-27	Велфайд Корпорейшн	Тиенотриазолодиазепиновые соединения и лекарственное средство
JPH11228576A (ja) *	1997-12-10	1999-08-24	Japan Tobacco Inc	アポトーシス抑制剤
CN1901958B (zh)	2003-11-03	2011-03-09	葛兰素集团有限公司	流体分配装置
SG115845A1 (en)	2004-03-31	2005-10-28	Univ Singapore	Modulation of trip-br function and method of treating proliferative disorders
GB0420970D0 (en)	2004-09-21	2004-10-20	Smithkline Beecham Corp	Novel triazoloquinoline compounds
WO2006129623A1 (ja)	2005-05-30	2006-12-07	Mitsubishi Tanabe Pharma Corporation	チエノトリアゾロジアゼピン化合物及びその医薬としての用途
JP2008156311A (ja)	2006-12-26	2008-07-10	Institute Of Physical & Chemical Research	Ｂｒｄ２ブロモドメイン結合剤
JP5478262B2 (ja)	2007-12-28	2014-04-23	田辺三菱製薬株式会社	抗癌剤
GB0919431D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds

2010
- 2010-08-06 KR KR1020127014637A patent/KR101424989B1/ko not_active Expired - Fee Related
- 2010-08-06 EP EP13192666.9A patent/EP2722334B1/en active Active
- 2010-08-06 DK DK10740654.8T patent/DK2496580T3/da active
- 2010-08-06 PT PT131926669T patent/PT2722334E/pt unknown
- 2010-08-06 EP EP10740654.8A patent/EP2496580B1/en active Active
- 2010-08-06 MX MX2012005295A patent/MX2012005295A/es active IP Right Grant
- 2010-08-06 ME MEP-2016-53A patent/ME02360B/me unknown
- 2010-08-06 CA CA2779355A patent/CA2779355C/en not_active Expired - Fee Related
- 2010-08-06 ES ES16150637.3T patent/ES2652304T3/es active Active
- 2010-08-06 HR HRP20140107AT patent/HRP20140107T1/hr unknown
- 2010-08-06 PT PT107406548T patent/PT2496580E/pt unknown
- 2010-08-06 PL PL13192666T patent/PL2722334T3/pl unknown
- 2010-08-06 HU HUE13192666A patent/HUE026421T2/en unknown
- 2010-08-06 SI SI201031117T patent/SI2722334T1/sl unknown
- 2010-08-06 ES ES10740654.8T patent/ES2446647T3/es active Active
- 2010-08-06 EP EP16150637.3A patent/EP3037423B1/en active Active
- 2010-08-06 ES ES13192666.9T patent/ES2563057T3/es active Active
- 2010-08-06 BR BR112012010706A patent/BR112012010706A2/pt active Search and Examination
- 2010-08-06 DK DK13192666.9T patent/DK2722334T3/en active
- 2010-08-06 MY MYPI2012001967A patent/MY160456A/en unknown
- 2010-08-06 RS RS20160102A patent/RS54592B1/sr unknown
- 2010-08-06 WO PCT/EP2010/061518 patent/WO2011054553A1/en not_active Ceased
- 2010-08-06 JP JP2012537329A patent/JP5524343B2/ja active Active
- 2010-08-06 NZ NZ599258A patent/NZ599258A/en not_active IP Right Cessation
- 2010-08-06 AU AU2010314395A patent/AU2010314395B2/en not_active Ceased
- 2010-08-06 PE PE2012000614A patent/PE20121181A1/es not_active Application Discontinuation
- 2010-08-06 PH PH1/2012/500894A patent/PH12012500894A1/en unknown
- 2010-08-06 CN CN201080050285.XA patent/CN102762569B/zh not_active Expired - Fee Related
- 2010-08-06 US US13/505,039 patent/US9023842B2/en active Active
- 2010-08-06 EA EA201290183A patent/EA020390B1/ru not_active IP Right Cessation
- 2010-08-06 RS RS20140088A patent/RS53179B/sr unknown
- 2010-08-06 SI SI201030514T patent/SI2496580T1/sl unknown
- 2010-08-06 PL PL10740654T patent/PL2496580T3/pl unknown
2012
- 2012-04-05 IL IL219090A patent/IL219090A0/en unknown
- 2012-04-18 DO DO2012000114A patent/DOP2012000114A/es unknown
- 2012-05-04 CL CL2012001178A patent/CL2012001178A1/es unknown
- 2012-05-10 CO CO12077201A patent/CO6540003A2/es unknown
- 2012-05-28 CR CR20120283A patent/CR20120283A/es unknown
- 2012-06-04 MA MA34934A patent/MA33803B1/fr unknown
2014
- 2014-02-18 CY CY20141100124T patent/CY1114988T1/el unknown
- 2014-02-20 SM SM201400024T patent/SMT201400024B/xx unknown
- 2014-11-30 IL IL235983A patent/IL235983B/en active IP Right Grant
2015
- 2015-04-13 US US14/684,659 patent/US20150210706A1/en not_active Abandoned
2016
- 2016-02-03 HR HRP20160119TT patent/HRP20160119T1/hr unknown
- 2016-03-01 CY CY20161100172T patent/CY1117479T1/el unknown
- 2016-03-22 SM SM201600081T patent/SMT201600081B/xx unknown
- 2016-07-13 HK HK16108220.7A patent/HK1220188A1/en unknown
2017
- 2017-01-20 US US15/410,874 patent/US20170197972A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20120099250A (ko)	2012-09-07
PE20121181A1 (es)	2012-09-13
EP2496580A1 (en)	2012-09-12
DK2722334T3 (en)	2016-03-07
RS53179B (sr)	2014-06-30
PT2496580E (pt)	2014-02-21
EP2722334A1 (en)	2014-04-23
IL235983A0 (en)	2015-01-29
HRP20160119T1 (hr)	2016-02-26
US20120220573A1 (en)	2012-08-30
IL219090A0 (en)	2012-06-28
NZ599258A (en)	2014-05-30
CR20120283A (es)	2012-08-14
CY1117479T1 (el)	2017-04-26
IL235983B (en)	2018-01-31
RS54592B1 (sr)	2016-08-31
PL2496580T3 (pl)	2014-06-30
EP2722334B1 (en)	2016-01-13
HK1220188A1 (en)	2017-04-28
CL2012001178A1 (es)	2012-10-05
AU2010314395A1 (en)	2012-05-24
CN102762569A (zh)	2012-10-31
MA33803B1 (fr)	2012-12-03
DK2496580T3 (da)	2014-02-24
ES2652304T3 (es)	2018-02-01
MX2012005295A (es)	2012-06-19
PL2722334T3 (pl)	2016-06-30
HK1175458A1 (en)	2013-07-05
US9023842B2 (en)	2015-05-05
WO2011054553A1 (en)	2011-05-12
JP5524343B2 (ja)	2014-06-18
CA2779355C (en)	2018-01-16
DOP2012000114A (es)	2012-08-15
EA020390B1 (ru)	2014-10-30
ME02360B (me)	2016-06-20
PT2722334E (pt)	2016-03-11
EP2496580B1 (en)	2013-12-11
US20150210706A1 (en)	2015-07-30
ES2446647T3 (es)	2014-03-10
SI2496580T1 (sl)	2014-02-28
SI2722334T1 (sl)	2016-03-31
PH12012500894A1 (en)	2022-03-09
BR112012010706A2 (pt)	2016-03-29
ES2563057T3 (es)	2016-03-10
HK1191012A1 (en)	2014-07-18
KR101424989B1 (ko)	2014-07-31
AU2010314395B2 (en)	2015-04-09
EP3037423B1 (en)	2017-09-20
CA2779355A1 (en)	2011-05-12
SMT201600081B (it)	2016-04-29
EP3037423A1 (en)	2016-06-29
CO6540003A2 (es)	2012-10-16
US20170197972A1 (en)	2017-07-13
CN102762569B (zh)	2015-04-01
MY160456A (en)	2017-03-15
CY1114988T1 (el)	2016-12-14
EA201290183A1 (ru)	2012-12-28
JP2013510107A (ja)	2013-03-21
HUE026421T2 (en)	2016-05-30
HRP20140107T1 (hr)	2014-04-25

Publication	Publication Date	Title
SMT201400024B (it)	2014-07-07	Inibitore del bromodominio di benzodiazepine
IL239625B (en)	2018-05-31	A benzodiazepine inhibits bromodomain
BRPI1008749A2 (pt)	2015-08-25	Derivados de benzodiazepina
EP2271347A4 (en)	2013-07-03	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS
SMT201600075B (it)	2016-04-29	Composto di diamminocarbossammide eterociclica
SMT201600098B (it)	2016-04-29	Antagonisti del complemento e loro usi
EP2272817A4 (en)	2011-12-14	PAI-1 INHIBITORS
EP2456440A4 (en)	2012-12-19	Quinolinone PDE2 INHIBITORS
ZA201404552B (en)	2015-06-24	Benzoxepin pi3k inhibitor compound and use thereof
BRPI0916295A2 (pt)	2019-09-24	inibidores de pirazolopiridina tricíclica cinase
EP2720699A4 (en)	2015-04-29	ADMINISTRATION OF BENZODIAZEPINE
KR101522157B9 (ko)	2024-07-31	Ｃｏｍｔ 억제제의 투약 방법
EP2691100A4 (en)	2014-09-24	INTRANASAL PHARMACEUTICAL BENZODIAZEPINE COMPOSITIONS
BRPI0922804A2 (pt)	2015-12-22	formas de dosagem sólidas de bendamustina
EP2413941A4 (en)	2012-10-10	Renin Inhibitors
LT2506840T (lt)	2021-06-25	Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
EP2480076A4 (en)	2013-03-13	IMIDOTHIAZOLKINASEINHIBITOREN
PT2774612T (pt)	2017-11-17	Formulações de 4-metilpirazol
EP2397481A4 (en)	2012-07-25	INHIBITOR OF CASEINKINASE 1DELTA AND CASEIN KINASE 1EPSILONE
SMT201500123B (it)	2015-09-07	Dosaggio unitario di apadenoson
EP2488530A4 (en)	2014-03-19	SPIROCYCLIC PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
TH0901003793A (th)	2016-06-03	สารประกอบไพร์โรโลไพริมิดีนและการใช้งานของสิ่งเหล่านั้น